Credit Suisse’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $425K | Buy |
+156,700
| New | +$378K | ﹤0.01% | 2705 |
|
|
2022
Q2 | – | Sell |
-68,392
| Closed | -$245K | – | 4137 |
|
|
2022
Q1 | $245K | Sell |
68,392
-970
| -1% | -$3.35K | ﹤0.01% | 3306 |
|
|
2021
Q4 | $272K | Buy |
69,362
+5,855
| +9% | +$27.4K | ﹤0.01% | 4160 |
|
|
2021
Q3 | $418K | Buy |
63,507
+4,767
| +8% | +$31.4K | ﹤0.01% | 3921 |
|
|
2021
Q2 | $362K | Sell |
58,740
-17,122
| -23% | -$91.5K | ﹤0.01% | 4016 |
|
|
2021
Q1 | $342K | Sell |
75,862
-9,691
| -11% | -$53.2K | ﹤0.01% | 3955 |
|
|
2020
Q4 | $513K | Buy |
+85,553
| New | +$562K | ﹤0.01% | 3787 |
|
|
2020
Q3 | – | Sell |
-10,578
| Closed | -$43K | – | 4082 |
|
|
2020
Q2 | $43K | Sell |
10,578
-88,226
| -89% | -$307K | ﹤0.01% | 3880 |
|
|
2020
Q1 | $250K | Buy |
98,804
+66,372
| +205% | +$218K | ﹤0.01% | 3532 |
|
|
2019
Q4 | $113K | Sell |
32,432
-11,767
| -27% | -$41.4K | ﹤0.01% | 4059 |
|
|
2019
Q3 | $204K | Sell |
44,199
-71,843
| -62% | -$566K | ﹤0.01% | 3857 |
|
|
2019
Q2 | $1.43M | Buy |
+116,042
| New | +$1.48M | ﹤0.01% | 2680 |
|
|
2018
Q2 | – | Sell |
-15,316
| Closed | -$89K | – | 4066 |
|
|
2018
Q1 | $89K | Buy |
15,316
+2,292
| +18% | +$15.1K | ﹤0.01% | 3816 |
|
|
2017
Q4 | $76K | Sell |
13,024
-7,027
| -35% | -$38.5K | ﹤0.01% | 3873 |
|
|
2017
Q3 | $100K | Buy |
+20,051
| New | +$84.3K | ﹤0.01% | 4091 |
|
|
2017
Q1 | – | Sell |
-11,365
| Closed | -$83K | – | 3942 |
|
|
2016
Q4 | $83K | Sell |
11,365
-22,247
| -66% | -$140K | ﹤0.01% | 3979 |
|
|
2016
Q3 | $269K | Sell |
33,612
-239
| -0.7% | -$2.19K | ﹤0.01% | 3691 |
|
|
2016
Q2 | $306K | Sell |
33,851
-34,669
| -51% | -$326K | ﹤0.01% | 3680 |
|
|
2016
Q1 | $553K | Buy |
68,520
+45,108
| +193% | +$325K | ﹤0.01% | 3178 |
|
|
2015
Q4 | $253K | Sell |
23,412
-39,240
| -63% | -$385K | ﹤0.01% | 3781 |
|
|
2015
Q3 | $507K | Sell |
62,652
-7,219
| -10% | -$114K | ﹤0.01% | 3374 |
|
|
2015
Q2 | $1.69M | Buy |
69,871
+28,639
| +69% | +$904K | ﹤0.01% | 2690 |
|
|
2015
Q1 | $1.74M | Buy |
41,232
+21,148
| +105% | +$836K | ﹤0.01% | 2509 |
|
|
2014
Q4 | $677K | Sell |
20,084
-50,356
| -71% | -$1.43M | ﹤0.01% | 3477 |
|
|
2014
Q3 | $1.73M | Sell |
70,440
-43,315
| -38% | -$1.22M | ﹤0.01% | 2605 |
|
|
2014
Q2 | $3.35M | Buy |
113,755
+58,569
| +106% | +$1.88M | ﹤0.01% | 2298 |
|
|
2014
Q1 | $2.43M | Buy |
55,186
+6,068
| +12% | +$267K | ﹤0.01% | 2370 |
|
|
2013
Q4 | $1.88M | Buy |
49,118
+34,604
| +238% | +$1.02M | ﹤0.01% | 2702 |
|
|
2013
Q3 | $318K | Sell |
14,514
-6,632
| -31% | -$130K | ﹤0.01% | 3769 |
|
|
2013
Q2 | $369K | Buy |
+21,146
| New | +$371K | ﹤0.01% | 3495 |
|
Other funds holding LAB
CC
AIM
NAMA
ICM
TM
Credit Suisse's LAB Position: Q1 2024 in Review
Credit Suisse opened a new position in Standard BioTools (LAB) in Q1 2024: 156,700 shares worth $425K. The stake represents ﹤0.01% of the portfolio and ranks #2705 among its holdings. This is a return to the name: Credit Suisse previously reported a position in LAB as recently as Q1 2022.
Credit Suisse first reported a position in LAB in Q2 2013 and has held it in 30 quarters since. The position peaked at $3.35M in Q2 2014. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2024.
- Credit Suisse held 156,700 shares of Standard BioTools worth $425K as of Q1 2024.
- Standard BioTools was a new Credit Suisse position in Q1 2024.
- Standard BioTools made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2705 holding.
- Credit Suisse first reported a position in Standard BioTools in Q2 2013 and has held it in 30 quarters since.
- Credit Suisse's Standard BioTools position peaked at $3.35M in Q2 2014.
- 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.